George Yancopoulos has a reputation for being unconventional (or perhaps outlandish to some). I would suggest that before he is taken seriously, Regeneron should publish a weight loss whitepaper explaining his position. At face value, it makes no sense to suggest that GLP-1 have some latent issues that goes beyond normal muscle loss as per the normal behavior for any weight loss.
Strength exercise are the normal suggestion to preserve muscle mass, and I don't believe there is any research showing this would not be effective with GLP-1 drugs.
An unconventional approach would be to take a GLP1 drug and ephedrine, which has been shown in many studies over 40 years to preserve muscle mass during calorie restriction. However, the drug is dirt cheap, not patentable for this common use, and therefore not of interest to any pharma company.
>Regeneron, a $111bn biotech that specialises in antibody treatments, is testing a drug called trevogrumab, which blocks the hormone myostatin, which limits muscle growth, in combination with Wegovy in mid-stage trials.
And there we have it. That explains why the founder is spreading FUD. He wants to sell more drugs into the same funnel. Ozempic wasting your muscles? Oh I got pills/injections/patches for that.
George Yancopoulos has a reputation for being unconventional (or perhaps outlandish to some). I would suggest that before he is taken seriously, Regeneron should publish a weight loss whitepaper explaining his position. At face value, it makes no sense to suggest that GLP-1 have some latent issues that goes beyond normal muscle loss as per the normal behavior for any weight loss.
Strength exercise are the normal suggestion to preserve muscle mass, and I don't believe there is any research showing this would not be effective with GLP-1 drugs.
An unconventional approach would be to take a GLP1 drug and ephedrine, which has been shown in many studies over 40 years to preserve muscle mass during calorie restriction. However, the drug is dirt cheap, not patentable for this common use, and therefore not of interest to any pharma company.
A recent meta analysis of ephedrine is here: https://www.mdpi.com/1424-8247/14/11/1198
https://archive.ph/FgcQB
>Regeneron, a $111bn biotech that specialises in antibody treatments, is testing a drug called trevogrumab, which blocks the hormone myostatin, which limits muscle growth, in combination with Wegovy in mid-stage trials.
And there we have it. That explains why the founder is spreading FUD. He wants to sell more drugs into the same funnel. Ozempic wasting your muscles? Oh I got pills/injections/patches for that.